Management team

AlzeCure Pharma AB was founded by the five scientists – Johan Sandin (CEO), Gunnar Nordvall, Pontus Forsell, Johan Lundkvist and Magnus Halldin – that all previously worked within the CNS research area at AstraZeneca.

The group has more than 100 years’ collective experience from research and development at several different pharmaceutical companies, including AstraZeneca, Merck Frosst and Orexo. They have published several studies in high ranking scientific journals and have contributed to that several drug candidates have been tested in clinical trials and also to the introduction of drugs to the market. The management team has a long experience in drug discovery and development within the Alzheimer field and a large network of collaborators.

Martin Jönsson
Martin Jönsson
CEO since January 8, 2020

Education/experience: Martin Jönsson has a MSc in business from University of Lund, and with studies at University of Freiburg, Germany and University of Ottawa, Canada. Martin Jönsson has more than 20 years’ experience in the global pharmaceutical industry, working for Roche and Ferring Pharmaceuticals, with senior positions in several different areas. He has worked with business development, sales, marketing, alliance management and medical affairs.

Current assignment: None

Completed assignments (last five years): Senior positions in several different areas at Ferring Pharmaceuticals.

Johan Sandin
Johan Sandin
CSO since January 8, 2020 (CEO 2017- January 7, 2020)

Education/experience: Johan Sandin has a Ph.D. from Karolinska Institutet, Sweden. Johan Sandin is a behavior pharmacologist within the neurology area with a large academic and industrial experience. He has 10 years of experience from AstraZeneca where he had several scientific, project and leadership roles with responsibility for in vitro biology, in vivo biology and biochemical biomarkers within the CNS area.

Current assignment: Member of the board and CEO at Sandin Pharma Consulting AB. Member of the board and deputy CEO at ArgusEye AB. Member of the board of AC Intressenter AB and Sinfonia Biotherapeutics AB. CEO of AlzeCure Discovery AB.

Completed assignments (last five years): None

Holdings: 850,000 shares.

Birgitta Lundvik
Birgitta Lundvik
CFO

Education/experience: Birgitta Lundvik has an MSc in business from Uppsala University and an eMBA in finance from Stockholm Business school, Sweden. Birgitta Lundvik has more than 25 years of experience from software development, life science and real estate companies. She has taken part in several M&A projects and has a broad experience of venture capital companies.

Current assignment: Chairman of the board of LobSor Pharmaceuticals AB. Member of the board and CEO of Enable – Finance & Business Development in Sweden AB. Secretary and Treasurer of Favro North America Inc. Deputy chairman of Swedsoft. Alternate member of the board of Helander & Lundvik Ekonomikonsulter AB, Balanced Competence Uppsala Redovisningsbyrå AB, Märsta Mur & Puts AB (unä) and Brf Arken.

Completed assignments (last five years): Member of the board and CEO of Hansoft Technologies AB. CEO of Favro AB and Nonna Holding AB.

Holdings: 65,000 shares.

Matthias Rother
Matthias Rother
Medical Director

Matthias Rother is a very experienced clinician that has work within the CNS field since the early 1990’s. Previous roles included Medical Director for Neuroscience at Hoechst (later Sanofi), Executive Director R&D at IDEA AG and Director Clinical Operations at X-pert-med GmbH. He has a long experience of designing clinical studies within the CNS area and has been involved in over 100 clinical studies in different phases of drug development.

Education: M.D. Friedrich-Schiller University, Jena, Germany.

Holdings: –

Gunnar Nordvall
Gunnar Nordvall
Director Medicinal Chemistry

Gunnar Nordvall is an expert in medicinal and computational chemistry with 30 years of experience from the Alzheimer and CNS area. Previously, he held several different positions at AstraZeneca such as team leader, project leader for several symptomatic Alzheimer’s projects and Principal Scientist in medicinal chemistry with responsibility for drug design.

Education: Pharmacist, Ph.D. in Medicinal chemistry from the Faculty of Pharmacy at Uppsala University, Sweden.

Holdings: 852,00 shares

Pontus Forsell
Pontus Forsell
Head of Discovery

Education/experience: Pontus Forsell has a Ph.D. in Medical Biochemistry & Biophysics from Karolinska Institutet, Sweden. Pontus Forsell has 20 years of experience from several biotech and pharmaceutical companies, such as Biolipox, Orexo, Merck and AstraZeneca in project and management positions. He is an expert in early phase drug discovery within the disease areas neurology, analgesia, as well as respiratory and inflammation.

Current assignment: Member of the board and CEO of Research, Education & Training AB (RETAB).

Completed assignments (last five years): None

Holdings: 853,643 shares.

Johan Lundkvist
Johan Lundkvist
Director Disease Biology

Johan Lundkvist has an academic career in neurobiology and dementia with a focus on Alzheimer’s disease and gamma-secretase biology. Johan was appointed associate Professor at Karolinska Institutet in 2005. He has 14 years of experience of drug discovery, including from AstraZeneca: team leader, project leader, member of the strategy team for neurology and responsible for project in-licensing to the neurology portfolio from academia.

Education: Ph.D. Neurochemistry and Neurotoxicology at Stockholm University, Sweden.

Holdings: 850,000 shares

Magnus Halldin
Magnus Halldin
Director DMPK

After post-doctoral studies in drug metabolism at UCSF, Magnus Halldin joined Astra in 1985 where he until 2013 contributed in many different management, project leader and scientific positions. He also contributed to bringing Ropivacaine and EMLA to the market. Magnus was also scientific DMPK advisor for large number global scientific committees and groups within AstraZeneca, and also part of the evaluation of in licensing opportunities and in due-diligence within both discovery and development.

Education: Pharmacist, Ph.D. from Faculty of Pharmacy at Uppsala University, Sweden.

Holdings: 850,000 shares

Holdings in AlzeCure Pharma AB as of September 30, 2019.